Evidence map›Paper›PMID 36678721›Full record

ArticlePharmaceutics2022

Lectin-Modified Magnetic Nano-PLGA for Photodynamic Therapy In Vivo.

Vera L Kovalenko, Elena N Komedchikova, Anna S Sogomonyan, Ekaterina D Tereshina, Olga A Kolesnikova, Aziz B Mirkasymov, Anna M Iureva, Andrei V Zvyagin, Petr I Nikitin, Victoria O Shipunova

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Internalization of transferrin-taggedExperimental biology and medicine (Maywood, N.J.) · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Vera L KovalenkoMoscow Institute of Physics and Technology, 9 Institutskiy Per., 141701 Dolgoprudny, Russia.
Elena N KomedchikovaMoscow Institute of Physics and Technology, 9 Institutskiy Per., 141701 Dolgoprudny, Russia.ORCID 0000-0002-5115-3774
Anna S SogomonyanShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10 Miklukho-Maklaya St., 117997 Moscow, Russia.
Ekaterina D TereshinaMoscow Institute of Physics and Technology, 9 Institutskiy Per., 141701 Dolgoprudny, Russia.
Olga A KolesnikovaMoscow Institute of Physics and Technology, 9 Institutskiy Per., 141701 Dolgoprudny, Russia.
Aziz B MirkasymovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10 Miklukho-Maklaya St., 117997 Moscow, Russia.ORCID 0000-0002-1275-8535
Anna M IurevaMoscow Institute of Physics and Technology, 9 Institutskiy Per., 141701 Dolgoprudny, Russia.
Andrei V ZvyaginShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10 Miklukho-Maklaya St., 117997 Moscow, Russia.ORCID 0000-0001-8799-2257
Petr I NikitinProkhorov General Physics Institute, Russian Academy of Sciences, 38 Vavilov Street, 119991 Moscow, Russia.ORCID 0000-0003-1573-5512
Victoria O ShipunovaMoscow Institute of Physics and Technology, 9 Institutskiy Per., 141701 Dolgoprudny, Russia.ORCID 0000-0001-6361-1042
Moscow Institute of Physics and Technology · RUInstitute of Bioorganic Chemistry · RUProkhorov General Physics Institute · RU

Funding

Priority 2030 agreement 075-02-2021-1316 30.09.2021Russian Science Foundation 21-74-30016Russian Science Foundation 22-73-10141
6 · The paper itself

Abstract

The extreme aggressiveness and lethality of many cancer types appeal to the problem of the development of new-generation treatment strategies based on smart materials with a mechanism of action that differs from standard treatment approaches. The targeted delivery of nanoparticles to specific cancer cell receptors is believed to be such a strategy; however, there are no targeted nano-drugs that have successfully completed clinical trials to date. To meet the challenge, we designed an alternative way to eliminate tumors in vivo. Here, we show for the first time that the targeting of lectin-equipped polymer nanoparticles to the glycosylation profile of cancer cells, followed by photodynamic therapy (PDT), is a promising strategy for the treatment of aggressive tumors. We synthesized polymer nanoparticles loaded with magnetite and a PDT agent, IR775 dye (mPLGA/IR775). The magnetite incorporation into the PLGA particle structure allows for the quantitative tracking of their accumulation in different organs and the performing of magnetic-assisted delivery, while IR775 makes fluorescent in vivo bioimaging as well as light-induced PDT possible, thus realizing the theranostics concept. To equip PLGA nanoparticles with targeting modality, the particles were conjugated with lectins of different origins, and the flow cytometry screening revealed that the most effective candidate for breast cancer cell labeling is ConA, a lectin from

Indexed as

allograftsConAimage-guided therapyIR775lectinmagnetic polymer nanoparticlesMPQphotodynamic therapyPLGA

Identifiers

PMID36678721
PMCPMC9862264
OpenAlexW4313415000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.